In the Boardroom
Refine Search
Biotechnology
US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
Anthony Harnden has been appointed as the new chair of the UK’s Medicine and Healthcare products Regulatory Agency (MHRA). 20 November 2024
Biotechnology
Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO). 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
Biotechnology
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
Pharmaceutical
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
Biotechnology
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Pharmaceutical
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Pharmaceutical
Switzerland-based Basilea Pharmaceutica has appointed David Veitch as its chief commercial officer. 19 August 2014
Biotechnology
British gene and cell therapy company Oxford BioMedica has appointed Paul Blake as chief development officer. 15 August 2014
Pharmaceutical
Coming from her position as president of Sanofi’s North American pharma division, Anne Whitaker has been named chief executive of Synta Pharmaceuticals. 12 August 2014
Pharmaceutical
Astellas Pharma EMEA, the regional headquarters of Japanese drug major Astellas Pharma, has appointed Simon Dew as chief strategy officer. 7 August 2014
Pharmaceutical
Biopharmaceutical company Receptos has appointed Mary Szela and Richard Heyman to the board of directors. 29 July 2014
Pharmaceutical
Quebec-based cardiovascular drug development specialist Milestone Pharmaceuticals has announced the appointment of Francis Plat as chief medical officer. He is a cardiologist with extensive experience in cardio drug development. 21 July 2014
Biotechnology
US-based Neurotrope, developers of diagnostic and therapeutic technologies for the treatment of neurodegenerative diseases, has announced the appointment of co-chairmen Charles Ramat and Paul Freiman as co-chief executives on an interim basis. 21 July 2014
Pharmaceutical
US-based drug development and discovery company Aptuit has appointed Paul Overton as executive vice president, business development and marketing. He is now responsible for all of Aptuit’s sales and marketing activities. 16 July 2014
Pharmaceutical
Bayer Corporation, a US subsidiary of German drug major Bayer has hired Malini Moorthy as head of its litigation department from July 30. 16 July 2014
Pharmaceutical
US-based clinical-stage biopharma company Xencor has announced the appointment of Kurt Gustafson to its board of directors. He will also serve as chair of the audit and compensation committees for the company which develops engineer monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. 15 July 2014
Pharmaceutical
US-based biopharma Anthera Pharmaceuticals has appointed Chuck Olson as president of its subsidiary Alkira Therapeutics. 15 July 2014
Pharmaceutical
Merck Serono, the biotech unit of Germany’s Merck KGaA, has announced the appointment of Luciano Rossetti as executive vice president and global head of research and development. 14 July 2014
Pharmaceutical
Taiwan-based pharmaceutical company ScinoPharm (TWSE: 1789) says that its president and chief executive will retire at the end of July after 17 years of service. He will be succeeded by Dr Yung-Fa (Fred) Chen, who is currently the company’s vice president of research and development, and chief technology officer, from August 1. 11 July 2014
Pharmaceutical
US-based oncology specialist Jounce Therapeutics has announced the appointment of Richard Murray to chief executive officer. Dr Murray has more than 20 years of experience in building research and development capabilities in small startups and large pharmaceutical companies. He replaces the interim chief executive, Cary Pfeffer. 11 July 2014
Biotechnology
UK-based biotech company Oxford BioTherapeutics, focusing on antibody-drug conjugates in the treatment of cancer, has announced the appointment of Eugen Leo as head of clinical development. 11 July 2014
article
Biochemist and cancer pharmacologist Paul Workman has joined Copenhagen-based pharmaceutical company Nuevolution as scientific advisor. 9 July 2014
Pharmaceutical
Danish allergy specialist ALK-Abello has appointed Helle Skov as new Executive Vice President (Product Supply) and member of the Board of Management of ALK-Abelló A/S. 1 July 2014
article
Specialist medical translation agency Conversis Medical has announced the appointment of Mark Hooper as Global Director with immediate effect. 26 June 2014
Biotechnology
Biotechnology firm Retrogenix has announces the appointment of Matthew Britz as North American Business Development Director with immediate effect. 23 June 2014
Generics
The chairman of Israel-based Teva Pharmaceutical Industries, the world’s largest generic drugs company, has indicated that he will step down from his position by year-end. 18 June 2014
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze